welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- When a Doctor Told Me ‘Helping Others with My Condition Should be Left to Trained Medical Professionals’At 30 years old, I’ve lived with shor...
- like a pork chop in a synagogue (resilience)I've seen some stuff, I've done some stu...
- Fay Kastrinos, MD, MPHAffiliation:NewYork-Presbyterian/C...
- Intestinal Polyps and Polyposis: State-of-the-Art, Multidisciplinary Publication on Polyps and PolyposisNowadays, we are dealing more frequently...
- James Church, MDJames M. Church, MD, is a staff member i...
- The Johns Hopkins Guide for Patients and Families: Familial Adenomatous PolyposisINTRODUCTION This booklet is written fo...
- antonio martin mayaGeneral and Colorectal Surgery - Institu...
English
Portuguese
Spanish